Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/168570
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | In silico analysis guides selection of BET Inhibitors for triple-negative breast cancer treatment |
Autor: | Pérez-Peña, Javier; Serrano-Heras, Gemma CSIC ORCID; Montero, Juan Carlos CSIC ORCID; Corrales-Sánchez, Verónica; Pandiella, Atanasio CSIC ORCID CVN ; Ocaña, Alberto | Fecha de publicación: | 2016 | Editor: | American Association for Cancer Research | Citación: | Molecular Cancer Therapeutics 15(8): 1823-1833 (2016) | Resumen: | Triple-negative breast cancer (TNBC) is an incurable disease with poor prognosis. At this moment, therapeutic options are limited to chemotherapy, and no targeted agent has reached the clinical setting. Bromodomain and extraterminal (BET) inhibitors are a new family of compounds that inhibit bromodomain-containing proteins affecting the expression of transcription factors, therefore modifying the expression of relevant oncogenic genes. In the present article, by using an in silico approach, we have identified the expression of upregulated transcription factors in TNBC compared with normal breast. Treatment with JQ1, a well-characterized BET inhibitor, modified some transcription factors, including DEP domain containing 1 (DEPDC), Forkhead box M1 (FOXM1), and Lim domain only 4 (LM04). In cell line models, administration of JQ1 or OTX015, another BET inhibitor, produced a significant antiproliferative effect and synergized with chemotherapies. Biochemical evaluation demonstrated an arrest at G as the main mechanism of action with a clear increase of p27. Addition of these compounds to chemotherapy induced apoptosis compared to each agent given alone. Evaluation of JQ1 in xenografted tumors in nude mice showed a profound antitumoral effect with a reduction of DEPDC, FOXM1, and LM04, in addition to an increase of p27. Globally, our data demonstrate the antitumor effect of this new family of compounds in TNBC, paving the way for its future clinical development. | URI: | http://hdl.handle.net/10261/168570 | DOI: | 10.1158/1535-7163.MCT-16-0004 | Identificadores: | doi: 10.1158/1535-7163.MCT-16-0004 e-issn: 1538-8514 issn: 1535-7163 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
18
checked on 08-abr-2024
SCOPUSTM
Citations
23
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
22
checked on 26-feb-2024
Page view(s)
256
checked on 23-abr-2024
Download(s)
76
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.